Used primarily in neuroscience research as a selective agonist for metabotropic glutamate receptor subtype 4 (mGluR4), CHPG helps investigate synaptic transmission and neuronal signaling pathways. It is utilized in studies related to neurodegenerative diseases, such as Parkinson’s disease, where mGluR4 modulation may offer therapeutic benefits. CHPG also aids in understanding the role of glutamate receptors in synaptic plasticity, learning, and memory. Due to its selectivity, it serves as a valuable tool for differentiating mGluR4-mediated effects from those of other glutamate receptor subtypes in cellular and tissue-based assays.